BioNTech Is No Longer a Buy, Says Analyst

·2-min read
BioNTech Is No Longer a Buy, Says Analyst

Despite some good news recently about the coronavirus vaccine it co-developed, BioNTech (NASDAQ: BNTX) has been hit with a recommendation downgrade. In a research note published on Tuesday, Bryan Garnier analyst Olga Smolentseva changed her view on the stock to neutral from the previous buy recommendation. At the same time, though, she significantly raised her price target on the stock, from $135 per share to $206.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting